Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

Receptor.AI and Sethera Plan to Create Closed-Loop Discovery and Optimization Workflow for Difficult Therapeutic Targets

Published

on

Receptor.AI and Sethera partner to create a closed-loop drug discovery workflow. Sethera will generate and experimentally screen architecture-diverse polymacrocyclic peptide libraries. Receptor.AI will apply physics-based modeling, artificial intelligence, and multiparameter optimization to interpret sequence, architecture, enrichment, and activity data; develop binding hypotheses; prioritize candidate series; and guide focused optimization cycles.

Subsequently, the companies will design, synthesize, and experimentally test new candidates, using the resulting data to inform each subsequent cycle.

Sethera’s platform installs one to six stable cross-links to generate polymacrocyclic, nested, in-line, and interpeptide structures across large, encoded libraries. Unlike constrained-peptide approaches centered on a predetermined structural motif, Sethera’s platform explores multiple experimentally accessible topologies, allowing target biology and screening data to identify the most productive molecular architecture, notes a Sethera spokesperson.

By combining this chemical space with Receptor.AI’s computational capabilities, the companies intend to advance screening-derived hits toward validated lead series with improved potency, selectivity, stability, permeability, and other developability characteristics.

The initial program will focus on a mutually selected hard-to-drug target. The companies will prospectively assess whether the integrated workflow improves hit confirmation, target selectivity, and lead optimization compared with conventional enrichment- and assay-led prioritization. Following validation of the initial workflow, Receptor.AI and Sethera intend to pursue additional internal programs and jointly structured discovery collaborations with pharmaceutical and biotechnology partners across selected target classes and therapeutic areas.

Alan Nafiiev, PhD
Alan Nafiiev, PhD

“Sethera’s platform creates experimentally accessible peptide architectures that conventional design approaches do not readily reach,” said Alan Nafiiev, PhD, founder and CEO of Receptor.AI. “Our objective is to use physics and AI not as a substitute for experimentation, but to learn from each experimental cycle and direct the next one. That closed feedback loop is where we believe the collaboration can create distinctive value.”

“Sethera can search enormous physical libraries and identify target-binding sequence and architecture families that cannot be generated through conventional peptide design alone,” adds Karsten Eastman, PhD, CEO and co-founder of Sethera Therapeutics. “Receptor.AI adds a powerful layer for understanding why those hits work and how they can be improved. Together, we intend to create a coordinated design-make-test-learn process that moves more efficiently from experimental discovery to validated lead series.”

Karsten Eastman, PhD
Karsten Eastman, PhD

The collaboration is specifically focused on applying Receptor.AI’s computational platform to Sethera’s proprietary polymacrocyclic peptide chemistry, encoded screening data, and resulting therapeutic candidates. Each company will retain its background platform technologies, and joint programs will be conducted under coordinated research plans with defined experimental, computational, data, and program-management responsibilities.

Through the alliance, Receptor.AI and Sethera officials say they aim to establish a repeatable discovery system that continuously learns from sequence, architecture, counterselection, binding, functional, and developability data generated across experimental campaigns. The resulting workflow is intended to reduce the number of design cycles required to progress from initial screening hits to differentiated peptide lead series.

 

 

The post Receptor.AI and Sethera Plan to Create Closed-Loop Discovery and Optimization Workflow for Difficult Therapeutic Targets appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

New webinar: Tackling drug discovery challenges in cancer research

Published

on

Cancer cells

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.

You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.

Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.

Q&A with the speakers follows the presentations.

Register for free now.

The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).

Continue Reading

Uncategorized

Psilocybin proves promising in neuropathic pain mouse study

Published

on

Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.

Continue Reading

Uncategorized

New Spectrometry Technique Could Aid Formulation Development

New Spectrometry Technique Could Aid Formulation Development

Published

on

A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.

According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.

“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”

Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.

The challenge is understanding the link between these things within a heterogeneous sample, he says.

To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.

He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.

Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.

Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.

The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Trending

Helixgate Biotech Review July Issue QR CodeScan to Read